{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:33:07Z","timestamp":1792103587478,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.prp.2024.155716","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:07:40Z","timestamp":1730999260000},"page":"155716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["LncRNA-mediated regulation of cisplatin response in breast cancer"],"prefix":"10.1016","volume":"264","author":[{"given":"Shirin","family":"Azizidoost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh","family":"Sheykhi-Sabzehpoush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahrokh Abouali Gale","family":"Dari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"J\u00f3zkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Niebora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Domaga\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Data","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Dzi\u0119giel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mozdziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Farzaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Kempisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155716_bib1","article-title":"Breast cancer: a review of risk factors and diagnosis","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.prp.2024.155716_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155716_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3233\/BD-201063","article-title":"Mini review: the FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer","volume":"40","author":"Khojasteh Poor","year":"2021","journal-title":"Breast Dis."},{"key":"10.1016\/j.prp.2024.155716_bib4","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155716_bib5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.32768\/abc.2024112116-117","article-title":"Immunohistochemical characterization of breast carcinoma: clinical correlations, molecular subtypes, and therapeutic implications: immunohistochemical characterization of BC","volume":"11","author":"Barodawala","year":"2024","journal-title":"Arch. Breast Cancer"},{"key":"10.1016\/j.prp.2024.155716_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2024.155716_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/0115743624264761231212055008","article-title":"Exploring the evolving significance of lncRNA TUG1-mediated signaling pathways in breast cancer","volume":"19","author":"Abouali Gale Dari","year":"2024","journal-title":"Curr. Signal Transduct. Ther."},{"key":"10.1016\/j.prp.2024.155716_bib8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.omtn.2021.08.005","article-title":"lncRNA and breast cancer: progress from identifying mechanisms to challenges and opportunities of clinical treatment","volume":"25","author":"Jin","year":"2021","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.prp.2024.155716_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.702082","article-title":"L-b: The role of non-coding RNAs in breast cancer drug resistance.","volume":"11","author":"Tian","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155716_bib10","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/nu16060800","article-title":"Healthy lifestyle and cancer risk: modifiable risk factors to prevent cancer","volume":"16","author":"Marino","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.prp.2024.155716_bib11","first-page":"1","article-title":"Body composition and chemotherapy toxicities in breast cancer: a systematic review of the literature","author":"Lewis","year":"2024","journal-title":"J. Cancer Surviv."},{"key":"10.1016\/j.prp.2024.155716_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102925","article-title":"Cisplatin: The first metal based anticancer drug","volume":"88","author":"Ghosh","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.prp.2024.155716_bib13","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3390\/ijms25063157","article-title":"Zeolitic imidazole framework\/silica nanocomposite for targeted cancer therapeutics: comparative study of chemo-drug cisplatin (CPt) and green platinum (GPt) efficacy","volume":"25","author":"Alotaibi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155716_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2023.215507","article-title":"Beyond cisplatin: new frontiers in metallodrugs for hard-to-treat triple negative breast cancer","volume":"499","author":"Muhammad","year":"2024","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.prp.2024.155716_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.30699\/jogcr.8.4.308","article-title":"Emerging role of the ceRNA-based MALAT-1-miRNA network in polycystic ovary syndrome","volume":"8","author":"Abouali Gale Dari","year":"2023","journal-title":"J. Obstet., Gynecol. Cancer Res."},{"key":"10.1016\/j.prp.2024.155716_bib16","first-page":"218","article-title":"Functional roles of lncRNAs in recurrent pregnancy loss: a review study","volume":"17","author":"Azizidoost","year":"2023","journal-title":"Int. J. Fertil. Steril."},{"key":"10.1016\/j.prp.2024.155716_bib17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11033-024-09546-x","article-title":"The long non-coding RNAs (lncRNA) in the pathogenesis of gastric cancer cells: molecular mechanisms and involvement miRNAs","volume":"51","author":"Saleh","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.prp.2024.155716_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1324393","article-title":"LncRNA as a regulator in the development of diabetic complications","volume":"15","author":"Geng","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.prp.2024.155716_bib19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12935-023-03202-3","article-title":"Interplay of miRNAs and lncRNAs in STAT3 signaling pathway in colorectal cancer progression","volume":"24","author":"Rahbar Farzam","year":"2024","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2024.155716_bib20","article-title":"Long non-coding RNA (lncRNA) roles in cell biology, neurodevelopment and neurological disorders","volume":"7","author":"Aliperti","year":"2021","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.prp.2024.155716_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100683","article-title":"Long non-coding RNAs as a determinant of cancer drug resistance: towards the overcoming of chemoresistance via modulation of lncRNAs","volume":"50","author":"Jiang","year":"2020","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.prp.2024.155716_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108642","article-title":"Cisplatin in the era of PARP inhibitors and immunotherapy","volume":"258","author":"Duan","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2024.155716_bib23","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.3390\/ijms25073820","article-title":"Transcriptomic changes in cisplatin-resistant MCF-7 cells","volume":"25","author":"Ruiz-Silvestre","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155716_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00894-024-05983-4","article-title":"Binding energies and hydrogen bonds effects on DNA-cisplatin interactions: a DFT-xTB study","volume":"30","author":"Ludwig","year":"2024","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.prp.2024.155716_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","article-title":"Cisplatin nephrotoxicity: new insights and therapeutic implications","volume":"19","author":"Tang","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.prp.2024.155716_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.mpmed.2023.12.007","article-title":"Drug-induced gastrointestinal disorders","author":"Norman","year":"2024","journal-title":"Medicine"},{"key":"10.1016\/j.prp.2024.155716_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2024.04.020","article-title":"Nanodrugs based on co-delivery strategies to combat cisplatin resistance","volume":"370","author":"Wang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2024.155716_bib28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.32604\/or.2023.030190","article-title":"Cisplatin-induced activation of TGF-\u03b2 signaling contributes to drug resistance","volume":"32","author":"Imatsuji","year":"2024","journal-title":"Oncol. Res."},{"key":"10.1016\/j.prp.2024.155716_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18342","article-title":"New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma","volume":"28","author":"Meneceur","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.prp.2024.155716_bib30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40261-024-01361-3","article-title":"Prediction model for severe thrombocytopenia induced by gemcitabine plus cisplatin combination therapy in patients with urothelial cancer","volume":"44","author":"Matsumoto","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.prp.2024.155716_bib31","first-page":"1838","article-title":"Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following \u03b2\u2011catenin silencing","volume":"45","author":"Zhu","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.prp.2024.155716_bib32","series-title":"Advances and Prospects of 3-d Metal-Based Anticancer Drug Candidates.","first-page":"169","article-title":"Biochemical mechanistic pathway of cell death induced by metal-based chemotherapeutic agents","author":"Arjmand","year":"2024"},{"key":"10.1016\/j.prp.2024.155716_bib33","first-page":"025","article-title":"Cisplatin-an overview of its efficiency and toxicity","author":"Djordjevi\u0107","year":"2023","journal-title":"Facta Univ., Ser.: Med. Biol."},{"key":"10.1016\/j.prp.2024.155716_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107310","article-title":"Design and synthesis of novel imidazole-chalcone derivatives as microtubule protein polymerization inhibitors to treat cervical cancer and reverse cisplatin resistance","volume":"147","author":"Liu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.prp.2024.155716_bib35","doi-asserted-by":"crossref","first-page":"9058","DOI":"10.1039\/D3DT01517C","article-title":"Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug's anticancer activity","volume":"52","author":"Ferraro","year":"2023","journal-title":"Dalton Trans."},{"key":"10.1016\/j.prp.2024.155716_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202300178","article-title":"Exploring the potential of metal-based candidate drugs as modulators of the cytoskeleton","volume":"24","author":"Borutzki","year":"2023","journal-title":"ChemBioChem"},{"key":"10.1016\/j.prp.2024.155716_bib37","unstructured":"Prabhakaran P.: Effects of cisplatin and interference peptides on triple negative breast cancers. 2014."},{"key":"10.1016\/j.prp.2024.155716_bib38","article-title":"Overcoming Cisplatin\u2019s challenges: a promising future in cancer care; a comprehensive review","volume":"13","author":"Nazari","year":"2023","journal-title":"Int. J. Med. Toxicol. Forensic Med."},{"key":"10.1016\/j.prp.2024.155716_bib39","article-title":"Cisplatin-based combination therapy for cancer","author":"Bhat","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.prp.2024.155716_bib40","doi-asserted-by":"crossref","first-page":"630","DOI":"10.21873\/invivo.13482","article-title":"Cisplatin induces kidney cell death via ROS-dependent MAPK signaling pathways by targeting peroxiredoxin I and II in african green monkey (Chlorocebus aethiops sabaeus) kidney cells","volume":"38","author":"Zhang","year":"2024","journal-title":"Vivo"},{"key":"10.1016\/j.prp.2024.155716_bib41","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/ijms25021130","article-title":"Role of epigenetics for the efficacy of cisplatin","volume":"25","author":"Lumpp","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155716_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/0115743624283095240308072648","article-title":"The role of long non-coding RNAs in the pathogenesis of essential hypertension","volume":"19","author":"Azizidoost","year":"2024","journal-title":"Curr. Signal Transduct. Ther."},{"key":"10.1016\/j.prp.2024.155716_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123657","article-title":"Non-coding RNAs as mediators of epigenetic changes in malignancies","volume":"12","author":"Kumar","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prp.2024.155716_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2023.103526","article-title":"The interactions between DNA methylation machinery and long non-coding RNAs in tumor progression and drug resistance","author":"Al-Imam","year":"2023","journal-title":"DNA Repair"},{"key":"10.1016\/j.prp.2024.155716_bib45","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.31557\/APJCP.2024.25.4.1169","article-title":"Long-noncoding-RNA HOTAIR upregulation is associated with poor breast cancer outcome: a systematic review and meta analysis","volume":"25","author":"Suwardjo","year":"2024","journal-title":"Asian Pac. J. Cancer Prev.: APJCP"},{"key":"10.1016\/j.prp.2024.155716_bib46","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41420-022-01174-3","article-title":"Functions and underlying mechanisms of lncRNA HOTAIR in cancer chemotherapy resistance","volume":"8","author":"Zhu","year":"2022","journal-title":"Cell death Discov."},{"key":"10.1016\/j.prp.2024.155716_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103141","article-title":"HOTAIR beyond repression: in protein degradation, inflammation, DNA damage response, and cell signaling","volume":"105","author":"Price","year":"2021","journal-title":"DNA Repair"},{"key":"10.1016\/j.prp.2024.155716_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720948447","article-title":"HOTAIR promotes cisplatin resistance of osteosarcoma cells by regulating cell proliferation, invasion, and apoptosis via miR-106a-5p\/STAT3 axis","volume":"29","author":"Guo","year":"2020","journal-title":"Cell Transplant."},{"key":"10.1016\/j.prp.2024.155716_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021130","article-title":"Role of Epigenetics for the Efficacy of Cisplatin","volume":"25","author":"Lumpp","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155716_bib50","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.7150\/jca.43446","article-title":"LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K\/AKT pathway","volume":"11","author":"Dai","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.prp.2024.155716_bib51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/OTT.S223321","article-title":"SNHG15 contributes to cisplatin resistance in breast cancer through sponging miR-381","author":"Mi","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.prp.2024.155716_bib52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.abb.2017.05.001","article-title":"Modulation of CASC2\/miR-21\/PTEN pathway sensitizes cervical cancer to cisplatin","volume":"623","author":"Feng","year":"2017","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.prp.2024.155716_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110216","article-title":"LncRNA TUG1 promotes bladder cancer malignant behaviors by regulating the miR-320a\/FOXQ1 axis","volume":"91","author":"Tan","year":"2022","journal-title":"Cell Signal"},{"key":"10.1016\/j.prp.2024.155716_bib54","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41420-021-00665-z","article-title":"Biological functions and clinical significance of long noncoding RNAs in bladder cancer","volume":"7","author":"Zhang","year":"2021","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.prp.2024.155716_bib55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.15252\/embr.201643139","article-title":"Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNPC-p53 protein interactions","volume":"18","author":"Shen","year":"2017","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.prp.2024.155716_bib56","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13046-019-1169-0","article-title":"SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF","volume":"38","author":"Saeinasab","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155716_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/cbin.11071","article-title":"miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1","volume":"43","author":"Yi","year":"2019","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.prp.2024.155716_bib58","doi-asserted-by":"crossref","first-page":"9239","DOI":"10.1080\/21655979.2021.1996305","article-title":"LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing MiR-381 in breast cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.prp.2024.155716_bib59","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1002\/ijc.32668","article-title":"IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer","volume":"146","author":"Kruger","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.prp.2024.155716_bib60","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.3390\/ijms22041931","article-title":"The role of IGF\/IGF-1R signaling in hepatocellular carcinomas: stemness-related properties and drug resistance","volume":"22","author":"Ngo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155716_bib61","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.gastro.2006.08.026","article-title":"Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA","volume":"132","author":"Panzitt","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.prp.2024.155716_bib62","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.2147\/OTT.S226040","article-title":"Long non-coding RNA HULC promotes the development of breast cancer through regulating LYPD1 expression by sponging miR-6754-5p","volume":"12","author":"Wang","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.prp.2024.155716_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215861","article-title":"HULC targets the IGF1R\u2013PI3K-AKT axis in trans to promote breast cancer metastasis and cisplatin resistance","volume":"548","author":"Zhou","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155716_bib64","doi-asserted-by":"crossref","first-page":"T69","DOI":"10.1530\/JME-17-0311","article-title":"40 years of IGF1: IGF1 receptor signaling pathways","volume":"61","author":"Hakuno","year":"2018","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.prp.2024.155716_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-021-02404-x","article-title":"K-w: LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta\u2011analysis and bioinformatics analysis.","volume":"21","author":"Hu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.prp.2024.155716_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108869","article-title":"Downregulation of long noncoding RNA HCP5 contributes to cisplatin resistance in human triple-negative breast cancer via regulation of PTEN expression","volume":"115","author":"Wu","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2024.155716_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02745-1","article-title":"The pathogenic roles of lncRNA-Taurine upregulated 1 (TUG1) in colorectal cancer","volume":"22","author":"Azizidoost","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"13","key":"10.1016\/j.prp.2024.155716_bib68","doi-asserted-by":"crossref","first-page":"15787","DOI":"10.18632\/oncotarget.7487","article-title":"LncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155716_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-017-0753-1","article-title":"LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2024.155716_bib70","first-page":"245","article-title":"MT1JP inhibits tumorigenesis and enhances cisplatin sensitivity of breast cancer cells through competitively binding to miR-24-3p","volume":"11","author":"Zhu","year":"2019"},{"key":"10.1016\/j.prp.2024.155716_bib71","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20202938","article-title":"MiR-24-3p as a prognostic indicator for multiple cancers: from a meta-analysis view","volume":"40","author":"Wang","year":"2020","journal-title":"Biosci. Rep."},{"issue":"12","key":"10.1016\/j.prp.2024.155716_bib72","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.ejca.2015.04.021","article-title":"Interplay between microRNAs and WNT\/\u03b2-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer","volume":"51","author":"Ghahhari","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2024.155716_bib73","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1087057104265040","article-title":"The use of 3-D cultures for high-throughput screening: the multicellular spheroid model","volume":"9","author":"Kunz-Schughart","year":"2004","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.prp.2024.155716_bib74","first-page":"45","article-title":"Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features","volume":"27","author":"Takagi","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.prp.2024.155716_bib75","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/carcin\/bgaa078","article-title":"lncMat2B regulated by severe hypoxia induces cisplatin resistance by increasing DNA damage repair and tumor-initiating population in breast cancer cells","volume":"41","author":"Garc\u00eda-Venzor","year":"2020","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.prp.2024.155716_bib76","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbrc.2018.11.019","article-title":"LncRNA DLX6-AS1\/miR-129-5p\/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling","volume":"507","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.prp.2024.155716_bib77","doi-asserted-by":"crossref","first-page":"12290","DOI":"10.1002\/jcb.28493","article-title":"Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p","volume":"120","author":"Li","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2024.155716_bib78","article-title":"Prognostic significance of microRNAs in glioma: a systematic review and meta-analysis","volume":"2019","author":"Zhang","year":"2019","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.prp.2024.155716_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720929983","article-title":"LncRNA DLX6-AS1 contributes to epithelial\u2013mesenchymal transition and cisplatin resistance in triple-negative breast cancer via modulating Mir-199b-5p\/paxillin axis","volume":"29","author":"Du","year":"2020","journal-title":"Cell Transplant."},{"key":"10.1016\/j.prp.2024.155716_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.01397","article-title":"MiR-199b-5p suppresses tumor angiogenesis mediated by vascular endothelial cells in breast cancer by targeting ALK1","volume":"10","author":"Lin","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.prp.2024.155716_bib81","doi-asserted-by":"crossref","first-page":"15980","DOI":"10.3390\/ijms242115980","article-title":"Fyn-mediated paxillin tyrosine 31 phosphorylation regulates migration and invasion of breast cancer cells","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155716_bib82","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/hep.31195","article-title":"Inflammation-Induced Long Intergenic Noncoding RNA (LINC00665) increases malignancy through activating the double-stranded RNA\u2013activated protein kinase\/nuclear factor kappa B pathway in hepatocellular carcinoma","volume":"72","author":"Ding","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2024.155716_bib83","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/jcb.29449","article-title":"LINC00665 induces gastric cancer progression through activating Wnt signaling pathway","volume":"121","author":"Yang","year":"2020","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2024.155716_bib84","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2147\/OTT.S241578","article-title":"LncRNA LINC00665 promotes prostate cancer progression via miR-1224-5p\/SND1 axis","author":"Chen","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.prp.2024.155716_bib85","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41419-019-2213-x","article-title":"LINC00665 promotes breast cancer progression through regulation of the miR-379-5p\/LIN28B axis","volume":"11","author":"Ji","year":"2020","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.prp.2024.155716_bib86","first-page":"3097","article-title":"Long non-coding RNA LINC00665 promotes metastasis of breast cancer cells by triggering EMT","volume":"24","author":"Zhou","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.prp.2024.155716_bib87","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.omtn.2019.02.010","article-title":"LINC00665 induces acquired resistance to gefitinib through recruiting EZH2 and activating PI3K\/AKT pathway in NSCLC","volume":"16","author":"Liu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.prp.2024.155716_bib88","article-title":"Linc00665 can predict the response to cisplatin-paclitaxel neoadjuvant chemotherapy for breast cancer patients","volume":"11","author":"Dai","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2024.155716_bib89","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13046-021-02015-4","article-title":"LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication","volume":"40","author":"Sheng","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2024.155716_bib90","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.yjmcc.2015.09.016","article-title":"CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis","volume":"89","author":"Ounzain","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.prp.2024.155716_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.210","article-title":"DNA replication: Mechanisms and therapeutic interventions for diseases","volume":"4","author":"Song","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.prp.2024.155716_bib92","doi-asserted-by":"crossref","first-page":"373","DOI":"10.32604\/oncologie.2021.017786","article-title":"Overexpression of lnc-ERP44-3: 6 causes cell death and sensitivity to cisplatin in breast cancer cell lines","volume":"23","author":"Flores-Contreras","year":"2021","journal-title":"Oncologie"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824006277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824006277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T18:43:04Z","timestamp":1732646584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824006277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":92,"alternative-id":["S0344033824006277"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155716","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LncRNA-mediated regulation of cisplatin response in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"155716"}}